Cardiovascular therapies and neuromodulation devices by CVRx

  • Alena Volkova
  • 17.11.2026
Barostim treatment adoption grows with Baylor Scott & White Health partnership
CVRx announced that Baylor Scott & White Health is continuing to expand patient access to Barostim for individuals living with heart failure. The update highlights a partnership with Baylor Scott ...
  • Mykhailo Ihnatenko
  • 13.11.2026
CVRx supports first Barostim implant at Glens Falls Hospital
CVRx has supported the first Barostim implant at Glens Falls Hospital by Dr. Brett Voigt and the Adirondack Cardiology team. This marks the introduction of a novel device therapy designed to ...
  • Mykhailo Ihnatenko
  • 12.11.2026
CVRx enables first Barostim implant access at Vassar Brother Medical Center
CVRx has announced a partnership with Vassar Brother Medical Center for the center's first Barostim implant procedure. This collaboration gives patients at the facility access to a novel device ...
  • Alena Volkova
  • 10.11.2026
CVRx celebrates 25th Barostim implant milestone at HCA Lawnwood Medical Center
CVRx announced that HCA Lawnwood Medical Center and its team have completed their 25th Barostim implant procedure, marking a notable operational milestone for the company. The update highlights ...
  • Yaroslav Dmytrenko
  • 06.11.2026
Revenue for CVRx climbs to 13.8 million dollars with U.S. implanting centers reaching 262
CVRx announced its financial results for the third quarter, posting total revenue of 13.8 million dollars. U.S. revenue accounted for 13.0 million dollars during the period. The number of active ...
  • Elena Nikulina
  • 03.11.2026
CVRx leads first BENEFIT-HF trial implantation in Ohio
CVRx announced that The Christ Hospital research team has implanted their first participant in the BENEFIT-HF trial, making it the first site in Ohio to achieve this milestone. The initiative, ...
  • Pavlo Kot
  • 21.10.2026
Endeavor Health completes initial Barostim device implant with CVRx partnership
CVRx has announced its support for Endeavor Health Northwest Community Hospital in expanding access to the Barostim device for patients with heart failure. The company specifically referenced the ...
  • Alena Volkova
  • 24.09.2026
CVRx releases case study on ambulatory hemodynamic changes in HFrEF patients
CVRx has announced the publication of a new case study aimed at healthcare providers, focusing on ambulatory hemodynamic changes and strategies for diuretic de-escalation in patients with heart ...
  • Alena Volkova
  • 22.09.2026
Baylor Scott and White Medical Center conducts initial Barostim implant with CVRx collaboration
CVRx announced a partnership with Drs. Ernesto Ruiz, Lazaros Nikolaidis, Afshin Ehsan, and David Daniel and the team at Baylor Scott and White Medical Center in Temple, Texas, for their first ...
  • Oksana Koneva
  • 03.09.2026
CVRx sets agenda for HFSA2026 to advance Barostim program growth
CVRx is inviting attendees to HFSA2026 for an in-depth discussion on building and sustaining a successful Barostim program. The event will feature a comprehensive look at patient identification, ...
  • Parshwa Turakhiya
  • 01.09.2026
Florida Medical Clinic Orlando Health debuts Barostim device in collaboration with CVRx
CVRx has announced a partnership with Dr. Gilbert Postler, Dr. Michol Cooper, and the team at Florida Medical Clinic Orlando Health for their first Barostim implant. This collaboration allows ...
  • Eugene Komchuk
  • 27.08.2026
CVRx enables first Barostim implant at Orlando Health Dr Phillips Hospital
CVRx supported physicians at Orlando Health Dr. Phillips Hospital in performing their first Barostim implant procedure. The hospital's team, including Dr. Mauricio Perez Martinez, Dr. Sotero ...
  • Andreas Kristo
  • 26.08.2026
CVRx advances innovative therapy with 10th Barostim implant at The Heart Hospital Baylor Plano
CVRx announced that The Heart Hospital Baylor Plano team has successfully completed their 10th Barostim implant procedure. Led by Dr. Aasim Afzal, Dr. Dennis Gable, Blen Daniel, NP, and Claire ...
  • Eugene Komchuk
  • 24.08.2026
CVRx secures Medicare Advantage coverage for Barostim therapy from Devoted Health
CVRx announced that Devoted Health will offer Medicare Advantage coverage for its Barostim therapy, effective July 17, 2026. Devoted Health is a national health insurance company with the eighth ...
  • Yulia Slavina
  • 19.08.2026
M Health Fairview receives first Barostim implant through CVRx collaboration
CVRx announced a collaboration with M Health Fairview and physicians Dr. Alexandra Mercel and Dr. Yauhen Tarbunou to deliver their first Barostim implant. This milestone brings novel device ...
  • Anastasiia Chabaniuk
  • 17.08.2026
CVRx unveils Barostim therapy process as Chief Medical Officer details device procedure
CVRx introduces an overview of Barostim therapy through its Chief Medical Officer, Dr. Philip Adamson, MD, MSc, FACC, FESC, FRCP (Ed). Dr. Adamson explains the key steps involved in the Barostim ...
  • Daria Chernytska
  • 15.08.2026
CVRx supports symposium with focus on heart failure treatment advances
CVRx is actively participating in the Kansas City Heart Rhythm Society Symposium this weekend, emphasizing its commitment to advancing care for heart failure patients. The company is highlighting ...
  • Olga Shendetskaya
  • 13.08.2026
CVRx advances with 6th Barostim implant completed at The Mount Sinai Hospital
CVRx announced the completion of its 6th Barostim implant at The Mount Sinai Hospital, highlighting a growing adoption of its innovative therapy for patients. The achievement was credited to the ...
  • Igor Krasulya
  • 11.08.2026
Barostim implant rollout at Staten Island University Hospital advances device availability, CVRx initiative
CVRx has announced a partnership with Staten Island University Hospital to deliver the hospital's first Barostim implant. This collaboration involved Dr. Kenneth Dulnuan, Dr. Jonathan Schor, ...
  • Olga Shendetskaya
  • 06.08.2026
CVRx unveils Barostim therapy to target underlying causes of heart failure
CVRx is introducing Barostim, a therapy aimed at targeting the underlying physiology of heart failure to improve how patients feel and function. Philip Adamson, MD, MSc, FACC, FESC, FRCP (Ed), ...
  • Dmytro Kharkov
  • 04.08.2026
Podcast appearance by CVRx executive spotlights heart failure treatment evolution
CVRx's Chief Medical Officer, Philip Adamson, MD, MSc, FACC, FESC, FRCP (Ed), recently participated in the Moving the Needle in Medicine podcast hosted by Dr. Adam Hajduczok. During the ...